Video

Dr. Alter on Trials and Ongoing Research in Kidney Cancer

Author(s):

Robert S. Alter, MD

Robert S. Alter, M.D. Co-chief, Urologic Oncology, John Theurer Cancer Center, on major trials and ongoing research in kidney cancer, in the spring of 2011.

Robert S. Alter, M.D. Co-chief, Urologic Oncology, John Theurer Cancer Center, on major trials and ongoing research in kidney cancer, in the spring of 2011.

Related Videos
Nitin Jain, MD
Kimmie Ng, MD, MPH
Marina Chiara Garassino, MD
Elias Jabbour, MD, professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Rahul Banerjee, MD, FACP
Seth Wander, MD, PhD
Piotr Rutkowski, MD
Javier Martín Broto MD, PhD
Nicolas Girard, MD
Thach-Giao Truong, MD, medical director, Melanoma Program, Cleveland Clinic
Related Content
FDA recap thumb
October 4th 2024

OncLive’s September Roundup of Key FDA Approvals in Oncology

Stephen Liu, MD; Sara A. Hurvitz, MD, FACP; S. Vincent Rajkumar, MD; Sumanta Kumar Pal, MD, FASCO; Shubham Pant, MD, MBBS
May 23rd 2024

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

Vijayakrishna Gadi, MD, PhD, of University of Illinois College of Medicine Chicago
October 1st 2024

HER2-Directed ADCs Spread Like Wildfire Across the Spectrum of Solid Malignancies

Neal Shore, MD, FACS
January 26th 2023

FDA Approval Insights: Nadofaragene Firadenovec in BCG-Unresponsive NMIBC

RCC: stock.adobe.com
October 1st 2024

Fecal Microbiota Transplantation Boosts Response to Pembrolizumab Plus Axitinib in mRCC

The FDA’s ODAC votes against the risk:benefit profile of frontline PD-1 inhibitors in select tumor types, osimertinib gains approval for select NSCLC, and more this week from OncLive.
September 28th 2024

The OncFive: Top Oncology Articles for the Week 9/22